American Diabetes Association
Browse
DC22-1478 04_IOBP_Race_Ethnicity_Supplemental_02-22-23.docx (285.05 kB)

The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children with Type 1 Diabetes

Download (285.05 kB)
figure
posted on 2023-03-31, 12:44 authored by Luz E. Castellanos, Steven J. Russell, Edward R. Damiano, Roy W. Beck, Viral N. Shah, Ryan Bailey, Peter Calhoun, Keisha Bird, Nelly Mauras, the Bionic Pancreas Research Group

  

Objective: We evaluated the performance of the iLet® bionic pancreas (BP) in non-Hispanic Whites (‘Whites’) and in Blacks, Hispanics, and others (‘Minorities’).

Research Design and Methods: A multicenter, randomized controlled trial evaluated glycemic management with the BP versus standard-of-care (SC) in 161 adult and 165 pediatric participants with type 1 diabetes over 13 weeks. 

Results: In Whites (N=240), the mean baseline-adjusted difference in 13-week HbA1c between the BP and SC groups was -0.45% (95% CI -0.61% to -0.29% [-4.9, -6.6 to -3.1 mmol/mol]; P<0.001), while this difference among Minorities (N=84) was -0.53% (-0.83% to -0.24% [-6.0, -9.2 to -2.8 mmol/mol]; P<0.001). In Whites, the mean baseline-adjusted difference in TIR between the BP and SC groups was 10% (7 to 12%; P<0.001), while in Minorities it was 14% (10 to 18%; P<0.001). 

Conclusions: The BP improves glycemic control in both Whites and Minorities and offers promise in decreasing health care disparities. 

Funding

Beta Bionics, Inc

Eli Lilly

U.S. Department of Health and Human Services > National Institutes of Health > National Institute of Diabetes and Digestive and Kidney Diseases 1UC4DK108612-01

Novo Nordisk

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC